Novel therapies for diabetic neuropathic pain and central nervous system diseases

 NeuroBo is focused on neurodegenerative diseases that affect millions of patients worldwide.

NeuroBo_Header_1500x916.jpg

NeuroBo Pharmaceuticals' novel lead candidate NB-01 is targeting diabetic neuropathic pain. NB-01 increases levels of the neurotrophin, nerve growth factor (NGF). NGF inhibits nerve cell death and promotes nerve regeneration. The compound, licensed from leading pharmaceutical company, Dong-A ST, is initiating a Phase III clinical trial in early 2019. NeuroBo Pharmaceuticals has a second compound focusing on Alzheimer's disease currently ready for an IND and a Phase IIa trial.

NeuroBo Pharmaceuticals was jointly founded by JK BioPharma Solutions, a company specializing in the development of new biopharmaceuticals, and Dr. Roy Freeman, a Harvard Medical School neurologist, to develop natural ethical medicines focused on neuroscience.

dkblue_grnline.jpg

TEAM

The NeuroBo team hails from various organizations within the pharmaceutical, diabetes, and biotech industries, yet the NeuroBo team has one shared goal: to bring life-changing and disease-modifying therapies to patients suffering from neurodegenerative diseases worldwide.  

With John L. Brooks III, a well-known executive within the life sciences industry, at the helm of the company, along with Dr. Mark Versavel, experienced senior clinical drug developer and clinical pharmacologist, and Dr. Nandan Padukone, a well-known biotech executive, NeuroBo is poised to revolutionize the way we approach treatments for neurodegenerative diseases.  

400pix_board_backgrounf.jpg